Methotrexate (MTX) is one of anti-metabolite and anti-folate chemotherapeutic agents for various cancers including CRC, and it is revealed that H19 can mediate MTX resistance by activating Wnt/β-catenin signaling in colorectal cancer cell line HT-29 (feng Wu et al., 2017). Here, H19 is linked to colorectal carcinoma.